By Exec Edge Editorial Staff GameSquare Holdings (NASDAQ: GAME) said it completed a $70 million public offering, fueling a major expansion into decentralized finance with the launch of a $100 million Ethereum-based treasury strategy. The capital raise significantly exceeded earlier...

Download the Complete Report Here By Rayk Riechmann With 12 successful SPAC transactions representing over $7 billion in enterprise value as an advisor or sponsor, Daniel Hennessy’s Hennessy Capital Group (HCG) has one of Wall Street’s most impressive track records...

Contact: Executives-Edge.com Rayk@capmarketsmedia.com

Download the Complete Report Here The wealth management world is undergoing a revolution. One likely victor for investors to consider is recently-listed Binah Capital Group, Inc. (Nasdaq: BCG), whose tech has what it takes to help financial advisors thrive in...

Contact: Executives-Edge.com Rayk@capmarketsmedia.com

By Daniella Parra Inventiva said Dr. Jason Campagna has been named President of R&D and Chief Medical Officer as Inventiva advances lanifibranor, its lead candidate for MASH, with topline Phase 3 results from the NATiV3 trial expected in the second...

By Karen Roman Ascentage Pharma Group International (Nasdaq: AAPG) said China’s National Medical Products Administration (NMPA) approved the use of lisaftoclax for the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma. The authorization makes lisaftoclax the first inhibitor of...

By Karen Roman Toronto-based biotech company Radiant Biotherapeutics announced the designation of Deborah Geraghty, Ph.D., as President and Chief Executive Officer. The company also appointed Stefan Larson, Ph.D., as Chair of the Board of Directors, and Ingmar Bruns, M.D., Ph.D.,...

By Karen Roman Ascentage Pharma Group International (Nasdaq: AAPG) said it designated Veet Misra, Ph.D., as Chief Financial Officer, and Eric Huang as Senior Vice President of Global Corporate Development and Finance. Dr. Misra has more than 20 years of...

By Karen Roman Oncology-focused biotech company SkylineDx said an independent study shows that Merlin CP-GEP, the company’s test for treatment decisions in early-stage melanoma, correctly categorizes patients with skin melanoma for sentinel lymph node biopsy (SLNB). Merlin acts as a...